{"id":3871,"date":"2017-07-23T04:34:31","date_gmt":"2017-07-23T04:34:31","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=3871"},"modified":"2017-07-23T04:48:53","modified_gmt":"2017-07-23T04:48:53","slug":"medicina-molecular-metabolismo-lipidico-y-riesgo-cardiovascular","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2017\/07\/23\/medicina-molecular-metabolismo-lipidico-y-riesgo-cardiovascular\/","title":{"rendered":"Medicina gen\u00f3mica, l\u00edpidos y riesgo cardiovascular"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2017\/07\/2017-07-22-ANGPTL3.jpeg\"><img loading=\"lazy\" class=\"alignleft wp-image-3894 size-full\" style=\"border-width: 1px;margin: 5px\" title=\"(c) Dewey FE et al. N Engl J Med 2017\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2017\/07\/2017-07-22-ANGPTL3.jpeg\" alt=\"2017 07 22 ANGPTL3\" width=\"85\" height=\"69\" \/><\/a>Dos estudios abordan las variantes gen\u00e9ticas en <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/gene\/27329\" target=\"_blank\">ANGPTL3<\/a>, inhibidor end\u00f3geno de la actividad de <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/gene\/4023\" target=\"_blank\">LPL<\/a>, y los resultados de su inhibici\u00f3n farmacol\u00f3gica con un anticuerpo monoclonal y oligonucle\u00f3tidos antisentido: Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, <em>et al<\/em>. <a title=\"Texto completo en ingl\u00e9s\" href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1612790#t=article\" target=\"_blank\">Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease<\/a>. N Engl J Med 2017;377:211-221, y Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, <em>et al<\/em>. <a title=\"Texto completo en ingl\u00e9s\" href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1701329#t=article\" target=\"_blank\">Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides<\/a>. N Engl J Med 2017;377:222-232.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dos estudios abordan las variantes gen\u00e9ticas en ANGPTL3, inhibidor end\u00f3geno de la actividad de LPL, y los resultados de su inhibici\u00f3n farmacol\u00f3gica con un anticuerpo monoclonal y oligonucle\u00f3tidos antisentido: Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[13,15,23,29,32],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3871"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=3871"}],"version-history":[{"count":6,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3871\/revisions"}],"predecessor-version":[{"id":3908,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3871\/revisions\/3908"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=3871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=3871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=3871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}